In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on RXi Pharmaceuticals Corp (NASDAQ: RXII), with a price target of $3. The company’s shares closed on Friday at $1.98, close to its 52-week low of $1.78.
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.2% and a 44.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for RXi Pharmaceuticals Corp with a $3 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.70 and a one-year low of $1.78. Currently, RXi Pharmaceuticals Corp has an average volume of 241.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
RXi Pharmaceuticals Corp. is a biotechnology company, which engages in developing therapeutics that address unmet medical needs. Its clinical product candidate includes RXI-109, a RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.
